10 Pump and Dump Stocks Favored by Hedge Funds

5. Cryoport, Inc. (NASDAQ:CYRX)

Number of Hedge Fund Holders: 20

Cryoport, Inc. (NASDAQ:CYRX) is a global provider of temperature-controlled supply chain solutions for the life sciences industry. It specializes in cryogenic logistics for biopharmaceuticals, including cell and gene therapies, clinical research, and reproductive medicine. The company offers specialized packaging, monitoring, and transportation services to ensure the integrity of temperature-sensitive biological materials. CYRX serves pharmaceutical companies, research institutions, and fertility clinics, generating revenue through logistics services, storage solutions, and equipment leasing. Its infrastructure supports regulatory-compliant, end-to-end supply chain management for critical biological shipments worldwide.

Cryoport, Inc. (NASDAQ:CYRX) concluded 2024 with solid results, achieving total annual revenues of $228.4 million in line with expectations despite a challenging year for life sciences. The Life Sciences Services business demonstrated strong performance with double-digit YoY growth in Biostorage and Bioservices revenue, representing 67% of total revenue compared to 62% the previous year. The company saw significant growth in commercial cell and gene therapy support, with revenues increasing by 37% in Q4 and 20% for the full year. CYRX supported a record 701 clinical trials by year-end, including 81 Phase III trials, and increased its commercial programs from 14 to 19.

Cryoport, Inc. (NASDAQ:CYRX) made substantial progress in improving its gross margin, which rose to 45.8% in Q4 2024 compared to 40.6% in the same period last year. Looking ahead to 2025, management provided revenue guidance in the range of $240 million to $250 million and expects to achieve positive adjusted EBITDA during the year. The company launched new initiatives including IntegriCell cryopreservation facilities in Houston and Liege, and introduced the revolutionary CXHV3 shipping system, positioning itself for future growth in the cell and gene therapy industry. Management anticipates 23 BLA or MMA filings could occur in 2025, up from 11 last year, with 3 filings already completed in January. With high stock price volatility in the last 52 weeks and 20 hedge fund holders, CYRX is one of the pump and dump stocks favored by hedge funds.